Edesa Biotech Reports Quarterly Financial Results

August 14, 2019 4:05 PM

TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business. During the quarter, Edesa completed its reverse acquisition and Nasdaq listing, and announced plans to proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which the company is...

Read more

Hancock Jaffe Reports Positive 90 Day Results for CoreoGraft Animal Feasibility Study

August 14, 2019 11:00 AM

Grafts Open and Fully Functional at 90 Days IRVINE, CA / ACCESSWIRE / August 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. For the three (3) test subjects that were evaluated via angiogram ninety (90) days post CoreoGraft bypass surgery, the CoreoGrafts are functioning...

Read more

Dyadic Reports Second Quarter 2019 Results and Recent Developments

August 13, 2019 4:00 PM

New Fully Funded Research Collaboration With a Top Tier Pharmaceutical CompanyExpanded Technology Platform Through Multiple Collaborations and Sublicensing AgreementsRobust Scientific Data ReportedUp listed to the Nasdaq Capital Market and Joined Russell Microcap® IndexJUPITER, FL / ACCESSWIRE / August 13, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and...

Read more

Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update

August 13, 2019 2:35 PM

Conference Call Scheduled for Thursday, August 15th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Second Quarter 2019 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a...

Read more

Great Bay Bio Adds Two Industry Leaders to Advisory Board

August 12, 2019 12:50 AM

Great Bay Bio Adds Two Industry Leaders to Advisory Board HONG KONG, CHINA / ACCESSWIRE / August 12, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce the establishment of its 3D Advisory Board. The board of directors eagerly welcome two top industry elites, Dr. Katie Su and Mr. Aaron Wang, to the company....

Read more

CBDual Biotechnology Corp (subsidiary of OTC: CBDG) to Offer ORALDNA(R) Testing to Improve Oral and Systemic Health

August 9, 2019 11:05 AM

THOUSAND OAKS, CA / ACCESSWIRE / August 9, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) developer of CBD based oral health products, today announced - that the Company is now offering a powerful new tool to help with gum disease diagnosis and treatment. A simple rinse test from OralDNA® Labs identifies individual genetic susceptibility to periodontal disease. With this information, clinicians are...

Read more

Molecular Partners Announces Appointment of Nicolas Leupin, M.D., MBA, as Chief Medical Officer

August 8, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / August 8, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced the appointment of Nicolas Leupin, M.D., MBA, to the role of Chief Medical Officer and Member of Management Board as of September 1, 2019. Dr. Leupin will succeed Chief Medical Officer Andreas Harstrick, M.D., who will remain with the...

Read more

Continuous Augmentation of Governance Structure, The Board of Great Bay Bio Welcomes a New Member

August 1, 2019 9:25 AM

HONG KONG, CHINA / ACCESSWIRE / August 1, 2019 / Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung. This is now a critical time for Great Bay Bio for rapid development of its core competitive competencies. The...

Read more

Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update

August 1, 2019 7:00 AM

Company to Host an Investor Conference Call on Thursday, August 1, 2019 at 8:00 AM EDT BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today reported its cash position for the second quarter of 2019 ended June 30, 2019, and...

Read more

Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

August 1, 2019 6:55 AM

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors. Dr. Said is the Founder and Chief Executive Officer of Outcomes4Me Inc., a health...

Read more

Angle PLC Announces Preliminary Results for the year ended 30 April 2019

July 31, 2019 2:00 AM

BUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET FDA SUBMISSION ON TRACK FOLLOWING POSITIVE RESULTS FROM BREAST CANCER CLINICAL STUDY GUILDFORD, SURREY / ACCESSWIRE / July 31, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces unaudited results for the year ended 30 April 2019. Operational Highlights 400 subject FDA clinical study enrolment using the Parsortix® system in...

Read more

Dyadic to Report Second Quarter 2019 Financial Results on Tuesday August 13, 2019

July 30, 2019 4:00 PM

JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its...

Read more

Applied BioSciences Provides Corporate Update and 2019 Business Outlook

July 30, 2019 8:00 AM

Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiativesPurposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing...

Read more

Principle Investigator Dr. Jorge Hernando Ulloa Reports New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean

July 26, 2019 8:31 AM

Reflux Now at Normal Levels in All Four VenoValve Patients IRVINE, CA / ACCESSWIRE / July 26, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, the Principle Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, reported new 90 day VenoValve data at the Second Annual...

Read more

Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45

July 25, 2019 9:36 AM

Company Enters the Multi-Billion Dollar CBD Market with Proprietary Instrument System Designed to Significantly Improve the Processing of CBD Oil into High Quality, Water-Soluble Nanoemulsions SOUTH EASTON, MA / ACCESSWIRE / July 25, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the...

Read more

Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019

July 25, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / July 25, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2019 investor call on Thursday, August 1, 2019 at 8:00 AM (EDT) to provide a corporate update. To access the call, participants...

Read more

Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study

July 25, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently evaluating investigational centers in the U.S. and expects to proceed with enrolling the...

Read more

Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services

July 24, 2019 9:14 AM

Company Expects Significant Services Revenue Increase in 2019 as it Expands its BaroFold Platform into the Estimated $44 Billion Global Bioprocess Technology Market SOUTH EASTON, MA / ACCESSWIRE / July 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life...

Read more

AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

July 22, 2019 8:01 PM

BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are $5.0 million. H.C....

Read more

NUMAFERM Closes Licensing Agreement with PEPDesign

July 22, 2019 8:30 AM

- Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM's unique technology platform - Industry seeks optimized generic drug manufacturing methods after liraglutide patent expiration DÜSSELDORF, GERMANY & PŪRĒ, LATVIA / ACCESSWIRE / July 22, 2019 / The Düsseldorf-based NUMAFERM GmbH has signed a licensing agreement for its unique manufacturing process for peptides with PEPDesign SIA. NUMAFERM's...

Read more